title: Clinical Outcome of Radioiodine Therapy in Low-intermediate Risk Papillary Thyroid Carcinoma with BRAF(V600E) Mutation.
abstract: Objective To evaluate the impact of BRAF(V600E) gene status on clinical outcome of radioiodine((131)I) therapy in low-intermediate risk recurrent papillary thyroid carcinoma (PTC). Methods Totally 135 PTC patients were enrolled and divided into two groups according to BRAF(V600E) gene status:BRAF(V600E) mutation group(n=105) and BRAF(V600E) wild group(n=30). The median follow-up time was 2.16 years(1.03-4.06 years),and clinical outcome after initial (131)I ablation therapy was divided into excellent response(ER),acceptable response(AR),and incomplete response(IR) according to the serological and imageological follow-up results. The cinical outcomes were then compared between these two groups. Results There was no significant difference in clinicopathological features and initial radioactive iodine dose between BRAF(V600E) mutation and wild groups (P>0.05). ER,AR,and IR after (131)I ablation therapy accounted for 74.3%,20.0%,and 5.7% in BRAF(V600E) mutation group and 73.3%,20.0%,and 6.7% in BRAF(V600E) wild group,and no statistical difference was found (P=0.891). Conclusion For low-intermediate risk recurrent PTC,BRAF(V600E) gene status may have no impact on the response to (131)I ablation therapy,and thus this molecular feature should not be used as an independent weighting factor for risk assessment in this population.
authors.affiliation: Department of Oncology,the Affiliated Hospital of Qingdao University,Qingdao,Shandong 266003,China.
authors.forename: Jiao
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Nuclear Medicine,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
authors.forename: Tao
authors.initials: T
authors.lastname: Yang
authors.affiliation: Department of Oncology,the Affiliated Hospital of Qingdao University,Qingdao,Shandong 266003,China.
authors.forename: Teng
authors.initials: T
authors.lastname: Zhao
authors.affiliation: Department of Oncology,the Affiliated Hospital of Qingdao University,Qingdao,Shandong 266003,China.
authors.forename: Jun
authors.initials: J
authors.lastname: Liang
authors.affiliation: Department of Nuclear Medicine,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
authors.forename: Yan-Song
authors.initials: YS
authors.lastname: Lin
mesh_terms: D002277:Carcinoma / Q000235:genetics / Q000532:radiotherapy*; D002291:Carcinoma, Papillary; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D009154:Mutation; D011379:Prognosis; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000235:genetics / Q000532:radiotherapy*
chemical_list: D007457:Iodine Radioisotopes; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf